Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-788 vs Platinum-Based Chemotherapy in First-Line NSCLC with EGFR Exon 20 Insertion Mutations
NCT04129502Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2020
- Primary completion
- Sep 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 24
01
Overview
A Phase 3 trial of mobocertinib in non-small cell lung cancer (NSCLC), sponsored by Takeda. Started Jan 2020; status: completed.
02
Drugs
mobocertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04129502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129502.